These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
146 related articles for article (PubMed ID: 35616365)
1. Efficacy and safety of vemurafenib in Langerhans cell histiocytosis (LCH): A systematic review and meta-analysis. Mohapatra D; Gupta AK; Haldar P; Meena JP; Tanwar P; Seth R Pediatr Hematol Oncol; 2023 Feb; 40(1):86-97. PubMed ID: 35616365 [TBL] [Abstract][Full Text] [Related]
2. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284 [TBL] [Abstract][Full Text] [Related]
3. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. Donadieu J; Larabi IA; Tardieu M; Visser J; Hutter C; Sieni E; Kabbara N; Barkaoui M; Miron J; Chalard F; Milne P; Haroche J; Cohen F; Hélias-Rodzewicz Z; Simon N; Jehanne M; Kolenova A; Pagnier A; Aladjidi N; Schneider P; Plat G; Lutun A; Sonntagbauer A; Lehrnbecher T; Ferster A; Efremova V; Ahlmann M; Blanc L; Nicholson J; Lambilliote A; Boudiaf H; Lissat A; Svojgr K; Bernard F; Elitzur S; Golan M; Evseev D; Maschan M; Idbaih A; Slater O; Minkov M; Taly V; Collin M; Alvarez JC; Emile JF; Héritier S J Clin Oncol; 2019 Nov; 37(31):2857-2865. PubMed ID: 31513482 [TBL] [Abstract][Full Text] [Related]
4. Successful treatment of Langerhans cell histiocytosis in an infant with vemurafenib: a case report and literature review. Li Q J Dermatolog Treat; 2023 Dec; 34(1):2279901. PubMed ID: 37941458 [TBL] [Abstract][Full Text] [Related]
5. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020. Tang X; Gao J; Ma ZG; Guo X; Li Q; Wan Z; Sun JJ Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688 [TBL] [Abstract][Full Text] [Related]
6. Vemurafenib provides a rapid and robust clinical response in pediatric Langerhans cell histiocytosis with the BRAF V600E mutation but does not eliminate low-level minimal residual disease per ddPCR using cell-free circulating DNA. Evseev D; Kalinina I; Raykina E; Osipova D; Abashidze Z; Ignatova A; Mitrofanova A; Maschan A; Novichkova G; Maschan M Int J Hematol; 2021 Dec; 114(6):725-734. PubMed ID: 34383272 [TBL] [Abstract][Full Text] [Related]
7. Cutaneous adverse events in children treated with vemurafenib for refractory BRAF Tardieu M; Néron A; Duvert-Lehembre S; Amine Larabi I; Barkaoui M; Emile JF; Seigneurin A; Boralevi F; Donadieu J Pediatr Blood Cancer; 2021 Sep; 68(9):e29140. PubMed ID: 34109735 [TBL] [Abstract][Full Text] [Related]
8. Somatic ARAF mutations in pediatric Langerhans cell histiocytosis: clinicopathologic, genetic and functional profiling. Liu R; Guo Y; Han L; Feng S; Cao J; Sun Y; Cao Z; Cui X Clin Exp Med; 2023 Dec; 23(8):5269-5279. PubMed ID: 37572153 [TBL] [Abstract][Full Text] [Related]
9. Vemurafenib combined with chemotherapy achieved sustained remission in pediatric LCH: a multi-center observational study. Lei J; Wang W; Lin D; Zhu C; Jia W; Weng W; Liu X; Ma Y; Wang Z; Yang L; He X; He Y; Li Y J Cancer Res Clin Oncol; 2024 Jan; 150(1):12. PubMed ID: 38231288 [TBL] [Abstract][Full Text] [Related]